GBI Research, May 2011, Pages: 69
.4 Upcoming Patent Expiries 11
3.5 Trends and Issues 11
3.5.1 ANDA Filings and Approvals are on the Rise 11
3.5.2 European Market for Small Molecule GenericDrugs versus Biosimilars 13
3.5.3 Untapped Generics
Decision Resources, Inc., July 2010, Pages: 40
in Japan are generally marginally higher than European prices but lower than U.S. prices. How do drug prices in Japan compare overall with pharmaceutical prices in the United States? To what extent do
Frost & Sullivan, Dec 2011, Pages: 213
Time is Ripe for Generics Manufacturers as Key Blockbuster Drugs Set to go Off-patent
The global generic pharmaceuticals market is likely to witness strong growth in the next few years owing
Decision Resources, Inc., April 2010, Pages: 35
companies, 13 Midsize Pharma companies, 20 generics companies, and 10 Big Pharma companies; generics companies; European and Japanese pharmaceutical companies active in neurology; marketed neurology drugs
Decision Resources, Inc., Aug 2009, Pages: 40
(ECJ) recently issued two judgments that could have significant repercussions for drug manufacturers.
- How much freedom do European governments have to impose price cuts or freezes on prescription
Venture Planning Group, Sep 2011
a worldwide strategic overview of the pharmaceutical market, including:
- Sales forecast for major product segments: ethical, OTC, generics.
- Sales forecast for major drug categories: cardiovascular
Global Industry Analysts, Inc., Sep 2008, Pages: 425
154
Investments in R & D 154
GenericDrugs 155
Table 93: European Market for GenericDrugs by Therapeutic
Category: Annual Sales Estimates in US$ Million for 2003
through 2008 for Cardiovascular
Business Insights, June 2011, Pages: 160
of drug candidates, and marketing of authorized generics, along with the development of first-in-line novel therapeutics might offset the effects of genericization. Features and benefits - Gain
Espicom Business Intelligence Ltd, March 2010, Pages: 128
and potentially provide a lucrative future for the generic industry.
Asthma/COPD: A valuable sector...
The biggest selling inhalable drugs for the treatment of asthma and/or COPD by value, are Glaxo
CYGNUS Business Consulting & Research, Aug 2011, Pages: 153
to be proved. In Europe, genericdrugs are approved by the European Medicines Agency (EMEA). In Japan, Pharmaceutical and Medical Devices Agency (PMDA) reviews the genericdrug application and the final approval
Spectra Intelligence, Nov 2011, Pages: 66
profile
Commercial opportunities
Potential pitfalls
Competition issues
European specific issues
Conclusions
Bibliography
Glossary
List of Figures
Figure 2.1 Global Time Line of Orphan Drug Legislation
Decision Resources, Inc., Sep 2006, Pages: 30
market: the unprecedented impact of generic simvastatin launches; review of the dynamic growth of the generics market in France.
Cost-containment programs: overview of several European countries’ initiatives to curb drug
Decision Resources, Inc., May 2010, Pages: 37
between the European Medicines Agency and the European Network for Health Technology Assessment; reimbursement restrictions for drugs of limited effectiveness in France; overhaul of the German pricing
Business Insights, Nov 2011, Pages: 154
and identify potential partners or rivals.
Highlights:
- New economic challenges coming to light in 2011 will further pressure the industry, making drug maker financial performance even more important
GBI Research, Dec 2010, Pages: 77
“Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” provides key data, information and analysis of the major trends and issues
Espicom Business Intelligence Ltd, June 2010, Pages: 248
The days when the Indian pharmaceutical industry was synonymous with cheap genericdrug production are passing. While generics continue to play a major part in the industry's success, many companies
Business Insights, April 2008, Pages: 147
and Europeandrug approval processes with this report’s detailed analysis of the key regulatory issues surrounding new molecular entities, genericdrug applications, indication expansions and drug safety
Decision Resources, Inc., Jan 2010, Pages: 30
pricing policies? What are the potential repercussions of the election result?
- European governments continue to focus on reference pricing and boosting the use of generics to contain pharmaceutical
Business Insights, April 2003, Pages: 190
The Europeangeneric marketplace is perplexing and complicated, full of contradictions and inconsistencies - manufacturers of genericdrugs are presented with unprecedented opportunities as large
Global Industry Analysts, Inc., July 2009, Pages: 1810
Market in Canada III-77
Generics to Offer Potential Cost Savings III-77
New Patented Drugs- Adding Costs but Little Value III-78
Two-level Drug Approval Process in Canada III-78
Policy Differences Affect Generic
